BioPharmSignal logoBioPharmSignal

Biotech News

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

Capricor Therapeutics (CAPR)Capricor TherapeuticsClinical readout

CAPR (CAPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is capr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

CAPRCapricor Therapeutics2026-07-29 14:05 EST

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-26 13:05 EST

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

TARAProtara Therapeutics2026-04-27 20:05 EST

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

TARAProtara Therapeutics2026-05-15 11:00 EST

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

PTCTPTC Therapeutics, Inc.2026-04-28 20:05 EST

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PHVSPharvaris2026-02-10 11:50 EST

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

MNPRMonopar2026-06-26 20:05 EST

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

MGTXMeiraGTx2026-04-16 11:00 EST

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MGTXMeiraGTx2026-04-14 12:30 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

ARWRArrowhead Pharmaceuticals2026-01-27 12:30 EST

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

View all latest news

Capricor Therapeutics

Capricor Therapeutics is a cell-therapy company focused on rare disease and muscle disorders, especially Duchenne muscular dystrophy. Its platform centers on regenerative and immunomodulatory biology.

Recent company news

CAPRCapricor Therapeutics2026-07-29 14:05 EST

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-07-27 15:00 EST

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-26 13:05 EST

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

CAPRCapricor Therapeutics2026-06-08 13:25 EST

Capricor Therapeutics to Present at Upcoming Investor Conferences

Stock data

Close
6.57 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States